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Abstract
Background: The cyclic AMP specific phosphodiesterase, PDE4D5 interacts with the -propeller
protein RACK1 to form a signaling scaffold complex in cells. Two-hybrid analysis of truncation and
mutant constructs of the unique N-terminal region of the cAMP-specific phosphodiesterase,
PDE4D5 were used to define a domain conferring interaction with the signaling scaffold protein,
RACK1.
Results: Truncation and mutagenesis approaches showed that the RACK1-interacting domain on
PDE4D5 comprised a cluster of residues provided by Asn-22/Pro-23/Trp-24/Asn-26 together with
a series of hydrophobic amino acids, namely Leu-29, Val-30, Leu-33, Leu-37 and Leu-38 in a 'Leu-
Xaa-Xaa-Xaa-Leu' repeat. This was done by 2-hybrid analyses and then confirmed in biochemical pull
down analyses using GST-RACK1 and mutant PDE4D5 forms expressed in COS cells. Mutation of
Arg-34, to alanine, in PDE4D5 attenuated its interaction with RACK1 both in 2-hybrid screens and
in pull down analyses. A 38-mer peptide, whose sequence reflected residues 12 through 49 of
PDE4D5, bound to RACK1 with similar affinity to native PDE4D5 itself (Ka circa 6 nM).
Conclusions: The RACK1 Interaction Domain on PDE4D5, that we here call RAID1, is proposed
to form an amphipathic helical structure that we suggest may interact with the C-terminal -
propeller blades of RACK1 in a manner akin to the interaction of the helical G- signal transducing
protein with the -propeller protein, G-.
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cAMP is a ubiquitous second messenger that regulates nu-
merous key physiological processes [1–6]. Its levels are de-
termined both by controls on its rate of synthesis through
adenylyl cyclase activity and its rate of degradation
through cAMP phosphodiesterase (PDE) activity [1]. A
large multigene family encodes many proteins that exhibit
PDE activity [6–13]. Of these, the PDE4 cAMP-specific
phosphodiesterases have attracted considerable attention
as inhibitors that are selective for them have behavioral,
anti-inflammatory and smooth-muscle relaxant activity in
humans [7,8,10,13–15]. PDE4 enzymes can be differenti-
ated from other cyclic nucleotides phosphodiesterase
(PDE) families on the basis of sequence differences in
their catalytic region and by their ability to be specifically
inhibited by the drug, rolipram [10]. They are also charac-
terized by unique regulatory regions located in the amino-
terminal half of the proteins, called Upstream Conserved
Regions 1 and 2 (UCR1 and UCR2) [7]. 'Long' PDE4 iso-
forms exhibit both UCR1 and UCR2, whilst 'short' isofor-
ms lack UCR1 and 'super-short' isoforms lack UCR1 and
have a truncated UCR2. In long PDE4 isoforms, UCR1
and UCR2 appear to interact with each other [16] in order
to form a regulatory module that mediates the functional
outcome of phosphorylation by PKA [17,18] and ERK
[19]. The mammalian PDE4s comprise a large family of
isoforms, encoded by four different genes (PDE4A,
PDE4B, PDE4C, and PDE4D), with additional diversity
being generated by alternative mRNA splicing and the use
of alternative promoters [10]. A characteristic feature of
these different isoforms is their unique N-terminal re-
gions, which are believed to play a key role in the intrac-
ellular targeting of these isoforms [1,10,20]. For example,
the different N-terminal regions of PDE4A1 [21,22] and
PDE4A4/5 [23,24] determine distinct patterns of intracel-
lular targeting. Thus PDE4A1 is an exclusively membrane-
associated species that is targeted to the Golgi, whilst
PDE4A4/5 is localised to perinuclear and cell cortical re-
gions in COS7 cells.
PDE4D5 is one of five different isoforms encoded by the
PDE4D gene and is found in a variety of tissues and cell
types, including the brain [25]. PDE4D5 can be distin-
guished from other PDE4D isoforms by the presence of a
unique amino-terminal region of 88 amino acids, which
is highly conserved among mammals [25]. We have re-
cently demonstrated [26] that this PDE4D isoform can in-
teract with the WD-repeat signalling "scaffold" protein,
RACK1 [27–30]. This was done using independent meth-
ods to demonstrate that RACK1 and PDE4D5 interact;
namely two-hybrid screening, pull-down assays with re-
combinant RACK1, binding studies with purified recom-
binant proteins, and also by co-immunoprecipitation of
native, endogenously expressed RACK1 and PDE4D5
[26]. Native forms of these two proteins thus interact in a
variety of different cell types [26]. RACK1 is a 36 kDa WD-
repeat protein that was first identified as a protein that
could bind to certain protein kinase C (PKC) isoforms
subsequent to their activation by either diacylglycerol or
phorbol esters such as PMA [27–30]. However, RACK1
has also been shown to interact with other proteins such
as the -subunit of integrins [31], the common beta-chain
of the IL-5/IL-3/GM-CSF receptor [32], the Epstein-Barr
virus cytoplasmic A73 protein [33] and SRC family tyrosyl
protein kinases [34]. Thus RACK1 appears to act as a scaf-
fold or anchor protein [30] as do other WD-repeat pro-
teins such as G and  '-COP [35–37].
Previously, it has been shown that a small cluster of 4 ami-
no acids in the unique N-terminal region of PDE4D5 is
needed for its interaction with RACK1 [26]. Here, using a
program of deletion and mutagenesis strategies we show
that a much more extensive surface within the unique N-
terminal region of PDE4D5 is needed, involving a series
of hydrophobic amino acids extending from Leu-29 to
Leu-38. We call this the RACK1 Interaction Domain,
RAID1 and suggest that it forms a helical region able to in-
teract with RACK1.
Results
Long PDE4 isoforms are characterised by the presence of
two blocks of sequence, called UCR1 and UCR2, located
between the conserved catalytic unit and the extreme N-
terminal region that is unique to each isoform (Fig. 1)
[10,38]. The unique amino-terminal region of PDE4D5
(Fig. 1) consists of a block of 88 amino acids that has no
homology with any of the other four PDE4D isoforms
[25]. We have demonstrated previously [26] that this re-
gion of PDE4D5 is necessary and sufficient for it to bind
to RACK1, thus explaining why PDE4D5 uniquely
amongst the PDE4D isoforms is able to interact with
RACK1. Within the PDE4D5 N-terminal region we discov-
ered [26] that the Asn-22/Pro-23/Trp-24/Asn-26 grouping
of amino acids (Fig. 1) was crucial in allowing PDE4D5 to
bind to RACK1. The discovery of this essential group of
amino acids was achieved through a strategy of progres-
sive N-terminal deletions and subsequent point muta-
tions within the 88 residue N-terminal region of PDE4D5
[26].
Mapping of the site for RACK1 interaction within the 
unique N-terminal region of PDE4D5
Using an ELISA assay, we confirmed previous observa-
tions [39], that PDE4D5 interacted with RACK1 with a Ka
of 4 – 12 nM (range; n = 5 separate experiments). In con-
trast to this, using both ELISA and TNT competition as-
says, we failed to observe any binding to RACK1 of a 5-
mer peptide (sequence = NPWLN) that contained the Asn-
22/Pro-23/Trp-24/Asn-26 grouping (Fig. 1), which we
had previously identified as being pivotal for interactionPage 2 of 11
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prised to discover that a 16-mer peptide (PEVDNPHCPN-
PWLNED), representing residues 13 to 28 of PDE4D5 and
thus also containing the Asn-22/Pro-23/Trp-24/Asn-26
grouping (Fig. 1), showed little if any interaction with
RACK1 (Ka > 1 M; n = 5).
These data suggested to us that amino acids in addition to
those within the Asn-22/Pro-23/Trp-24/Asn-26 grouping
might be involved in allowing the efficient binding of
PDE4D5 to RACK1. We thus set out to try and identify
such determinants. The discovery of the Asn-22/Pro-23/
Trp-24/Asn-26 grouping was based upon a strategy of pro-
gressive N-terminal deletions of the 88 residue N-terminal
region of PDE4D5, followed by scanning mutagenesis of
amino acids Pro-21 through Glu-27. Thus any additional
RACK1-interacting residues must be C-terminal to the
Asn-22/Pro-23/Trp-24/Asn-26 grouping. To evaluate this
we instigated a strategy of progressive C-terminal trunca-
tion of the unique N-terminal region of PDE4D5 in a 2-
hybrid screen. We have previously confirmed [26] the fi-
delity of such an approach by using a variety of independ-
ent biochemical analyses, including co-
immunoprecipitation, pull down assays with GST-RACK1
and the binding of purified components. The full N-ter-
minal region of PDE4D5 interacted with RACK1, as did
the 12–88 N-terminal truncate in this 2-hybrid analysis
(Fig. 2). However, the C-terminally truncated construct,
encompassing residues 12 through 28 of PDE4D5, failed
to interact with RACK1 (Fig. 2), despite the fact that such
a region contained the Asn-22/Pro-23/Trp-24/Asn-26
grouping. Such a result indicates strongly that additional
residues, located C-terminal to the Asn-22/Pro-23/Trp-
24/Asn-26 grouping, are required for PDE4D5 to bind to
RACK1. Further truncation analyses demonstrated that a
C-terminal truncate, containing residues 12 through 49 of
PDE4D5, was able to bind to RACK1 (Fig. 2). This sug-
gests that certain amino acids, located within positions 27
through 49 in the sequence of PDE4D5, are also required
for RACK1 interaction.
Previously we have shown [26] that Glu-27 was not in-
volved in RACK1 interaction. Here then we set out to de-
termine which specific amino acids in the 28 through 49
region of PDE4D5 are necessary for the interaction with
RACK1. Again, a 2-hybrid assay was used to test for the ef-
Figure 1
The unique N-terminal region of PDE4D5 This shows schematically the domain structure of the PDE4D5 long isoform
together with the amino acid sequence (GenBank™ accession number AF012073) of its unique 88 residue N-terminal region.
Indicated by a horizontal arrow is the sequence of both the 16-mer and 38-mer peptides that were assessed for binding to
RACK1. In bold typeface are shown the residues of the essential Asn-22/Pro-23/Trp-24/Asn-26 grouping and also those that
form the essential hydrophobic ridge, Leu-29, Val-30, Leu-33, Leu-37 and Leu-38. Also indicated are the positions of the vari-
ous truncated species made with associated residue numbers.
catalytic region
UCR1 UCR2Unique N-terminal region
C-terminal
region
Long form splice
junction LR1 LR2
MAQQTSPDTLTVPEVDNPHCPNPWLNEDLVKSLRENLLQHEKSKTARKSVSPKLSPVISPRNSPRLLRRMLLSSNIPKQRRFTVAHT
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no acid in this region was separately mutated to alanine
except for the hydrophobic amino acids that were
changed to aspartate and Ser-32 that was changed to both
alanine and aspartate. This analysis highlighted a single
residue, Leu-33, whose mutation to either aspartate (Fig.
3) or glutamate (not shown) ablated the interaction with
RACK1. No other single mutations in the 28 through 49
region of PDE4D5 served to ablate interaction with
RACK1 (data not shown), although we did observe a
marked reduction in interaction with the Arg34Ala mu-
tant (Fig. 3).
We noted, however, that the region C-terminal to the Asn-
22/Pro-23/Trp-24/Asn-26 grouping contained a series of
three leucine residues interposed by three amino acids in
the repeat sequence Leu-29, Xaa, Xaa, Xaa, Leu-33, Xaa, Xaa,
Xaa, Leu-37. This is reminiscent of hydrophobic repeat
motifs that are found in amphipathic helical regions
where coiled-coil forms of protein – protein interactions
occur [40–43]. This repeat in PDE4D5 contains Leu-33,
which we show here (Fig. 3) to be essential for PDE4D5 to
interact with RACK1. As Leu-29 and Leu-37 both have hy-
drophobic residues immediately adjacent to them, name-
ly Val-30 and Leu-38, we surmised that our inability to
ablate interaction with RACK1 using single mutations
might be due to contributions from these adjacent hydro-
phobic residues. We thus set out to evaluate whether mu-
Figure 2
Truncation studies within the unique N-terminus of
PDE4D5 used to probe its interaction with RACK1
using a 2-hybrid screen. Plasmids encoding fusions
between the DNA-binding domain of LexA and various
amino terminal regions of PDE4D5 were tested for their abil-
ity to interact with RACK1, expressed as a fusion with the
GAL4 activation domain (left column "pGADN-RACK1").
The identical LexA fusions were tested for their ability to
interact with the GAL4 activation domain alone (right col-
umn "pGADN"). The regions of PDE4D5 included in the var-
ious constructs are annotated. The positions of the portions
of PDE4D5 used in this study are shown schematically in Fig-
ure 1. The interactions between these components were
evaluated with the filter beta-galactosidase assay described
previously by us [16,26]. The bottom two patches serve as
internal positive (being the interaction between the oncopro-
teins RASv12 and RAF) and negative (vectors with inserts)
controls, respectively.
pGADN
pGADN
RACK1
1-746
1-88
12-88
12-69
12-49
12-38
12-28
Vector
+ ctr - ctr
Figure 3
Identification of residues involved in the interaction
between PDE4D5 and RACK1 using a 2-hybrid
screen. Shows a typical experiment of one done at least 3
times, where mutations of individual or pairs of residues in
the indicated N-terminal region of full length PDE4D5 were
expressed as LexA fusions of the non-mutated PDE4D5 (1–
746), pGADN-RACK1 and LexA alone ('vector'). The inter-
action between the oncoproteins RASv12 and RAF served as
a positive control
+ ctr
1-746
L29D
V30D
L33D
R34A
E35A
R34A, E35A
L37E, L38E
L37D, L38D
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interaction with RACK1. Indeed the mutation of the Leu-
29:Val-30 pair, to either aspartate (Fig. 3) or to glutamate
(not shown), served to ablate interaction with RACK1.
Similarly, mutation of the Leu-37:Leu38 pair, to either as-
partate or to glutamate, also ablated interaction with
RACK1 (Fig. 3). This suggests to us that these repeated hy-
drophobic residues are important in the binding of
PDE4D5 to RACK1. We did note, however, that Leu-25,
within the Asn-22/Pro-23/Trp-24/Asn-26 grouping, is
also located three residues N-terminal to Leu-29 and thus
falls within a repeating Leu, Xaa, Xaa, Xaa, Leu unit. How-
ever, previously we have shown that, unlike other residues
within the Asn-22/Pro-23/Trp-24/Asn-26 grouping, the
mutation of Leu-25 to alanine did not ablate binding to
RACK1. In this study we additionally mutated Leu-25, to
either aspartate or to tryptophan, with no ablation of
RACK1 interaction as assessed by 2-hybrid analysis (data
not shown). Thus Leu-25 does not appear to be essential
for interaction with RACK1 in the way that either the sur-
rounding residues in the Asn-22/Pro-23/Trp-24/Asn-26
grouping are or as Leu-33 has been shown to be (Fig. 3).
We also explored various other pairs of amino acids
through their simultaneous mutation to alanine; predom-
inantly to evaluate residues that might be involved in
charge-charge or hydrogen bonding interactions. These
were the pairs Arg-34/Glu-35, Gln-39/His-40, Glu-41/Lys-
42, Ser-43/Thr-45 and Arg-47/Lys-48. Of these, only the
double mutant, involving Arg-34/Glu-35, attenuated the
interaction. This reduction in signal was clearly less than
the ablated signal seen, for example, with the Leu33Asp
mutation (Fig. 3). However, the apparent reduction in sig-
nal was comparable to that seen with the single Arg34Ala
mutant (Fig. 3; right panel). In contrast to this, the single
Glu35Ala mutant showed a similar signal to the control,
wild-type PDE4D5 construct (Fig. 3). This suggests that
Arg-34 and not Glu-35 plays a role in mediating the inter-
action between PDE4D5 and RACK1.
We wished to provide independent confirmation that res-
idues in addition to those forming the Asn-22/Pro-23/
Trp-24/Asn-26 grouping were important in the interac-
tion between PDE4D5 and RACK1. To do this, the various
Leu33Asp, Leu37Asp:Leu38Asp, Leu37Glu:Leu38Glu and
Arg34Ala mutants were created in a VSV epitope-tagged
version of PDE4D5 and transiently expressed in COS7
cells. Extracts from these cells were then subjected to a
pull-down assay with GST-RACK1 as done before by us
[26]. This analysis (Fig. 4) demonstrated that all of these
mutations disrupted the interaction between PDE4D5
and RACK1. These data (Fig. 4) are consistent with the
Figure 4
Pull down assays to probe the interaction between PDE4D5 and RACK1. Pull down assays between RACK1 and
PDE4D5 mutants were done as described in Methods. Shown are immunoblots for VSV-epitope tagged forms of full length
PDE4D5 detected using an anti-VSV monoclonal antibody. Tracks 1 to 5 are immunoblots of cell lysates showing that equal
amounts of immunoreactive material were taken for these pull-down studies. Tracks 6 to 10 are blots showing the 'pull-
downs', namely material that is found associated with glutathione agarose-immobilized GST-RACK1. Full length PDE4D5 forms
were used as either wild type (tracks 1, 6) or the mutant forms Leu33Asp (tracks 2, 7), Arg34Ala (tracks 3, 8),
Leu37Asp:Leu38Asp (tracks 4, 9) and Leu37Glu:Leu38Glu (tracks 5, 10). These data are typical of experiments done at least
three times.
1 2 3 4 5 6 7 8 9 10
PDE4D5
lysate pull down
wt
L33A
R34A
L37D:
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L37E:
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al region of interaction within the unique N-terminal re-
gion of PDE4D5 that is essential for interaction with
RACK1.
Whilst the 12–38 truncate of PDE4D5 contained both the
Asn-22/Pro-23/Trp-24/Asn-26 grouping and the essential
hydrophobic ridge, it failed to bind to RACK1 in the 2-hy-
brid screen (Fig. 2). It should be noted, however, that the
final two residues of this truncated segment, namely Leu-
37 and Leu-38, are together essential for allowing interac-
tion with RACK1. It is thus highly likely that either steric
influences or disruption of appropriate helix formation
through replacement with 'foreign' residues, immediately
C-terminal to Leu-37 and Leu-38 in the 2-hybrid con-
struct, underpins this observation.
A 38-mer peptide, comprising residues 12–49 of PDE4D5,
contains both the previously identified Asn-22/Pro-23/
Trp-24/Asn-26 grouping [26] and also the novel leucine
repeat unit shown also to be crucial for RACK1 to bind to
PDE4D5. This peptide bound to RACK1 with similar
affinity1 (Ka of 6.4  1.2 nM (Mean  SD; n = 3 separate
experiments) to that reported for PDE4D5 [39]. This is
consistent with the 2-hybrid screen done in this study
(Fig. 2), which indicated that the construct expressing
amino acids 12 to 49 of PDE4D5 interacted with RACK1
in a similar fashion to full length PDE4D5. Thus the core
PDE4D enzyme does not have any profound effect on the
functional capability of the N-terminal region of PDE4D5
to interact with RACK1.
Molecular modeling
Molecular modeling studies (Fig. 5a), as well as the pro-
tein structure prediction programs, PHD and SSpro (data
not shown) [44], suggest that the RACK1 Interacting Do-
main 1, RAID1 that we have identified here in PDE4D5 is
likely to form a helical structure. In this the essential hy-
drophobic residues (Leu-29, Val-30, Leu-33, Leu-37, Leu-
38) is suggested to provide a distinct hydrophobic ridge
along one face of an amphipathic helix (Fig. 5a). This hy-
drophobic ridge (Fig. 5a) appears to comprise 3 key sticky
'patches', with 'patch 1' formed by Leu-29 and Val-30,
'patch 2' by Leu-33 and 'patch 3' by Leu-37 and Leu38.
Destruction of any one of these patches in its entirety suf-
fices to ablate interaction with RACK1. However, single
mutations, to the charged amino acid aspartate, within ei-
ther patch 1 or patch 3 are not sufficient to ablate interac-
tion of PDE4D5 with RACK1.
At the N-terminal 'head' of this proposed hydrophobic
ridge is found the Asn-22/Pro-23/Trp-24/Asn-26 group-
ing that is also essential for interaction of PDE4D5 with
RACK1. Leu-25 (Fig. 5a) appears at first glance to form a
simple continuation of this hydrophobic ridge into the
Asn-22/Pro-23/Trp-24/Asn-26 grouping. However, its
mutagenesis to a range of charged and aromatic amino ac-
ids did not affect the ability of PDE4D5 to interact with
RACK1, suggesting that Leu-25 has little or no role in de-
termining the interaction between these two proteins.
Thus the Asn-22/Pro-23/Trp-24/Asn-26 grouping and the
Figure 5
Modeling RAID-RACK1 interactions. (a) Surface repre-
sentation of RAID1 core segment, Asn-22 to Leu-38, as a
helix, with sidechains curtailed at the C atom for clarity.
Residues implicated in RACK1 binding are colour-coded on a
yellow helical background; blueAsn-22, Pro-23, Trp-24, Asn-
26, Arg-34, and purple Leu-29, Val-30, Leu-33, Leu-37, Leu-
38. These residues tend to align along one side of the helix.
(b) G (blue) – G (yellow) interactions from protein data
bank coordinate set '1got,' with a molecular surface (white)
drawn for the WD repeats 5–7 of G (lacking the initial -
strand of WD repeat 5 that is associated with the previous
propeller blade). (c) Electrostatic potential surface of com-
parative modeled RACK1 WD repeats 5–7 (equivalent part
and in the same orientation as that drawn for G in panel b).
Red denotes negative, blue positive, and white is non-polar.
(d) RACK1 mutations that affect RAID binding are drawn in
green on a molecular surface for WD repeats 5–7. (e) Model
for RACK1-RAID interactions, with the core RAID segment
of panel a forming the right-hand helix, that connects through
a loop to a positive region of RAID that is modeled (left-hand
helix) into a negative part of the RACK1 surface. Colour
coding for the RACK1 surface follows that in panel 2, and
that for the core RAID segment follows panel a. Arg-34 is at
the back of the helical ribbon and not visible in this view. The
orientation matches panels b,c, and d, so that general fea-
tures can be compared with G-G.
(b) G :G interactions
(c) RACK1:5-7 charge surface
(d) RACK1:5-7 binding mutations
(e) Model for RACK1: 5 -7 - RAID  interactions
G  Nt
G  Ct
(22)NPWLNEDLVKSLRENLLQHEKSKTARKS(49)
49
22
N
P
W
L
N
E
D
LV
K
SL
R
E
N
LL
(a) RAID motif on helixPage 6 of 11
(page number not for citation purposes)
BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1472-2091/3/24proposed hydrophobic ridge that encompasses Leu-29,
Val-30, Leu-33, Leu-37 and Leu-38 appear to form two
discrete units within RAID1 that are each essential for
PDE4D5 to bind to RACK1.
Discussion
We have defined here a sub-domain, which is located
within the unique 88 amino acid N-terminal region of
PDE4D5, that allows PDE4D5 to bind to the signaling
scaffold protein, RACK1. This region was defined using in-
dependent methodologies of 2-hybrid assays and bio-
chemical pull-down assays. We propose calling this region
RAID1, for RACK1 Interacting Domain 1. RAID1 is locat-
ed in the N-terminal half of this 88 amino acid isoform-
specific region of PDE4D5, extending from Asn22 to
Val30. It consists of a small cluster of amino acids, namely
the Asn-22/Pro-23/Trp-24/Asn-26 grouping [26], together
with a series of hydrophobic amino acids, namely Leu-29,
Val-30, Leu-33, Leu-37 and Leu-38 in a 'Leu-Xaa-Xaa-Xaa-
Leu' repeat.
The WD-repeat protein G, illustrated in Fig. 5b, interacts
with the G protein through coiled-coil interactions be-
tween the N-terminal regions of each subunit, and
through helical and non-helical segments of the G C-ter-
minus, interacting largely with propeller blades 5–7 at the
C-terminus of G[35,36,43,45]. Hydrophobic surfaces
play a large role in these interactions. Using a truncation
strategy coupled with a reverse 2-hybrid screen, we [46]
have demonstrated that the C-terminal region of RACK1
plays a crucial role in conferring the binding of PDE4D5.
Indeed, various single amino acid mutations in this re-
gion of RACK1 serve to ablate the binding of PDE4D5
[46]. Using colour coding of modeled RACK1 repeats 5–7
we identify here regions of particular polarity (Fig. 5c) as
well as those that have been implicated through mutagen-
esis in binding PDE4D5 (Fig. 5d). Whilst RACK1 lacks an
equivalent to the N-terminus of G, which mediates the
helical coiled-coil interactions with G, [45] these muta-
genesis data and surface properties indicate that PDE4D5-
RACK1 interactions may occur in a manner generally akin
to that for the C-terminal regions of G and G. We have
attempted to explore this possibility in the model shown
in Fig. 5e. The starting point for the model (Fig. 5e) is
placement of RAID1, modeled as a helix (Fig. 5a), adja-
cent to the mutagenesis-implicated groove on RACK1
(Fig. 5d). Of the other major surface regions highlighted
in Fig. 5d, that to the far right, by comparison with Fig. 5b,
forms internal interactions and the upper central green
feature is due to a single extended residue, R245, which
would appear to be sufficiently flexible as to allow, in
principle, an interaction with E35 in the PDE4D5 N-ter-
minal region. Having placed the core segment of RAID1 in
the model, we note that a second helical segment, con-
taining a positively charged region of the PDE4D5 N-ter-
minus, could be positioned to interact with a negatively
charged region of RACK1 (Fig. 5c). Thus Fig. 5e shows
both segments of the model, with a short connecting loop
that mediates a change in helical direction. We note that
in overall terms the model has similarities with G-G
binding [35,36,43,45], using helical segments binding
into grooves and intervening turns. The reverse direction
of the RAID1 polypeptide chain relative to G, on the pro-
peller surface, results from docking the positively charged
RAID1 segment into a negatively charged part of the
RACK1 model. Since the role of this part of RAID1 in
binding is not clear, we regard this element of the mode-
ling as secondary to the primary location of the amphip-
athic RAID1 helix in the RACK1 groove having the
identified [46] multiple binding mutants. This primary
docking could in fact be accomplished with either direc-
tion of polypeptide chain, so that we assign less weight to
our suggestion of RAID1 running opposite to G than to
the proposed binding groove for the core RAID segment.
Interestingly, Sondek and Siderovski ([47]), based on the
established interaction between G and G, used 3D-mod-
eling analyses to propose that protein-protein interaction
involving the C-terminal region of -propeller proteins
may be directed by putative G-protein Gamma-Like
(GGL) motifs on the binding partner. Indeed, they went
on to suggest that the Asn-22/Pro-23/Trp-24/Asn-26
grouping, in the unique N-terminus of PDE4D5, might re-
semble such a GGL domain and therefore bind to the C-
terminal region of RACK1 in a similar region to that where
G and G have been shown to interact. Thus, by analogy
with the GGL model ([47]), Asn-22/Pro-23/Trp-24/Asn-
26 may represent a common core motif as seen with ho-
mologous proteins. If this is the case then the specificity of
interaction must come from additional structural motifs
that either enhance or reduce interaction with particular
-propeller proteins. On this basis, we suggest that the
leucine-rich region, which we have identified in the
present study, may serve primarily to direct specificity for
interaction of RAID1 with RACK1 rather than other -pro-
peller proteins. The existence of this type of "structural
conditioning" would mean that a particular family of -
propeller proteins could have different specificity with re-
gards to their protein-binding partners. Additionally, for
each -propeller protein there may be a family of proteins
that can even interact at one 'site'. From the 3D-models
presented in this study (Fig. 5) we can see that WD 5–7 of
RACK1 contains a range of different interaction sites and
therefore may accommodate a range of possible interac-
tors; including those that bind weakly by only interacting
with a small part of the surface, and those that interact
strongly, like RAID1 (Fig. 5), which interact with multiple
determinants over an extended surface.
We also noted, however, that mutation, to alanine, of the
positively charged residue, Arg-34 ablated PDE4D5 inter-Page 7 of 11
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tenuated interaction in 2-hybrid screens. This indicates
that Arg-34 is also important in defining the binding of
PDE4D5 to RACK1. Arg-34 is proposed as being located
within the helix that contains the hydrophobic ridge and
is adjacent to the negatively charged Glu-35. In our model
it is possible that Arg-34 could either interact directly with
RACK1, perhaps through Asp-294, adjacent in the model,
or perhaps by virtue of non-polar interactions mediated
by the aliphatic part of an arginine sidechain. Whilst, po-
tentially, it could also stabilise a bound helical segment
through interaction with Glu-35 we consider this to be
unlikely as the Glu35Ala mutation interacts with RACK1
akin to wild-type PDE4D5.
Conclusions
Thus, an amphipathic helical conformation is suited to
the part of PDE4D5 that we show here is essential for its
binding to RACK1, namely Leu-29, Val-30, Xaa, Xaa, Leu-
33, Arg-34, Xaa, Xaa, Leu-37, Leu-38. This helix may pro-
vide the driving force for an initial interaction between
PDE4D5 and RACK1 that is then further stabilized
through the correct presentation of the essential Asn-22/
Pro-23/Trp-24/Asn-26 grouping. The structural model
that we propose may describe such an interaction suggests
that binding of PDE4D5 to RACK1 may involve interac-
tions that are akin to those seen for the binding of the G
protein to G in terms of helix/groove nature and overall
location. This interaction may thus allow PDE4D5 to be
recruited into a signaling scaffold complex where RACK1
acts as an adaptor. Our definition of the interaction do-
main, RAID1 should aid in the design of reagents aimed
at disrupting the interaction between PDE4D5 and
RACK1 so as to use them to gain insight into the physio-
logical function of such interaction in intact cells. Certain-
ly, the targeting of PDE species is likely to contribute to
the generation of compartmentalised cAMP responses
[10]. Indeed, there is currently much interest in identify-
ing anchor proteins for protein kinase A (AKAPs) that,
seemingly, serve to sample gradient of cAMP within cells,
leading to the selective activation of specific PKA isoforms
that are associated with particular signalling functions
[5,48,49].
Methods
Materials
An antibody to RACK1 was obtained from Transduction
Laboratories. A monoclonal antibody to the VSV epitope
tag [50] was from Sigma. The polyclonal antiserum specif-
ic for PDE4D was as described before by us [25]. Peptides
were from Cambridge Biosciences (Cambridge, UK) and
were determined to be >98% pure with composition veri-
fied by HPLC and mass spectrometry.
Two-hybrid constructs and assays
Various segments of the PDE4D5 cDNA (GenBank™ ac-
cession number AF012073) were cloned into the Not I
site of the vector pLEXAN, to generate fusions between the
various amino-terminal portions of PDE4D5 and the
DNA binding domain of the E. coli LexA protein [26]. pL-
EXAN is a derivative of pBTM116, with a Not I site insert-
ed into the polylinker. These constructs were prepared by
the addition of Not I sites to the cDNA regions by the use
of PCR, as described previously by us [26,51,52]. Similar-
ly, the full open reading frame (ORF) of human RACK1
cDNA (ref. [28]; GenBank accession number M24194)
was cloned into the Not I site of pGADN, to produce
pGADNRACK1. pGADN is a derivative of pGADGH, but
with a Not I site inserted into the polylinker. This vector
expresses proteins as in-frame fusions with the trans-acti-
vation domain of the S. cerevisiae GAL4 protein. Two hy-
brid assays were performed in the S. cerevisiae strain L40
using methods that we have described in detail previously
[16,26,52].
Generation of bacterial expression constructs
Various portions of the PDE4D5 cDNA were cloned into
the Not I site of pMALN, using PCR as described above for
the LexA fusions. pMALN is a derivative of pMALC2 (New
England Biolabs), with a Not I site inserted into the
polylinker. All PCR-generated or mutant constructs were
verified by sequencing prior to use.
Generation of cDNAs encoding mutant forms of PDE4D5
To generate mutations of one or two individual amino ac-
ids in PDE4D5, the full-length PDE4D5 cDNA [25] was
subjected to site-directed mutagenesis with the Quik-
Change site-directed mutagenesis kit (Stratagene). All
PCR-generated or mutant constructs were verified by se-
quencing prior to use.
Expression of glutathione S-Transferase (GST) and mal-
tose binding protein (MBP) fusion proteins in E. coli
The generation, expression and purification of fusion pro-
teins between the full ORF of RACK1 and both glutath-
ione-S-transferase (GST) and maltose-binding protein
(MBP) have been described in detail previously by us [26].
RACK1 pull-down assays
The construction of pcDNAPDE4D5VSV has been de-
scribed previously by us [26]. It contains the full ORF of
PDE4D5, with a vesicular stomatitis virus (VSV) glycopro-
tein epitope at the carboxyl terminus [50], cloned into
pcDNA3 (Invitrogen). Transfection of COS7 cells and
pull-down assays were performed as described previously
by us [25,26]. Briefly, COS7 cells were transfected with 20
g of control plasmid pcDNA3 or with 20 g of plasmid
pcDNAPDE4D5VSV encoding wild type VSV-tagged
PDE4D5, or with 20 g of plasmidsPage 8 of 11
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pcDNAPDE4D5R34AVSV (Arg34Ala),
pcDNAPDE4D5L3738DVSV (Leu37Asp:Leu38Asp),
pcDNAPDE4D5L3738EVSV (Leu37Glu:Leu38Glu) en-
coding various mutant forms of VSV-tagged PDE4D5 (as
indicated in parentheses). 72 h after transfection, cells
were harvested in lysis buffer (55 mM Tris-HCl, pH 7.4,
132 mM NaCl, 22 mM sodium fluoride, 11 mM sodium
pyrophosphate, 1.1 mM EDTA, 5.5 mM EGTA, 0.1% (v/v)
Triton X-100 plus protease inhibitors) and incubated for
a further 1 h with rotation at 4C. Cell debris was removed
by centrifugation at 13,000 g for 10 min at 4C. 400 g of
cleared lysate was incubated with 50 g of GST or GST-
RACK1 and 60 l of glutathione-Sepharose beads for 2 h
at 4C with rotation. Beads were pelleted by centrifuga-
tion at 2000 g for 5 min at 4C, washed three times in lysis
buffer and then boiled in 75 l Laemmli buffer. 50 l sam-
ples from beads and 50 g each of cleared lysate were an-
alysed by SDS-PAGE followed by immunoblotting with
an anti-VSV monoclonal antibody [25,26].
SDS polyacrylamide gel electrophoresis and immunoblot-
ting
These were as described previously [25,26]. In brief, sam-
ples were resuspended in Laemmli buffer and boiled for 5
min. Membranes were blocked in 5 % (w/v) low-fat milk
powder in TBS (10 mM Tris-HCl, pH 7.4, 150 mM NaCl)
overnight at room temperature. They were then incubated
with anti-VSV monoclonal antibody diluted in 1:5000 (v/
v) in 1 % (v/v) low-fat milk powder in TTBS (TBS plus 0.1
% (v/v) Tween 20) for 3 h at room temperature. Detection
of the bound antibody was with anti-mouse IgG peroxi-
dase (Sigma) and the enhanced chemiluminescence
(ECL) system (Amersham).
Measurement of protein concentrations
Protein concentrations were measured by the method of
Bradford [53], using BSA as a standard.
ELISA binding assay
A modification of the method described previously by us
[26] was used. High binding ELISA plates were treated
with 100 l of MBP-PDE4D5, MBP alone or various pep-
tides at a concentration of 1 M in 50 mM carbonate-bi-
carbonate buffer (Sigma C-3041) for 16 h at 4C. The
plates were then blocked in 5% (w/v) low-fat milk powder
in above buffer for 1 h at room temperature. Plates were
washed three times with 200 l/well wash buffer (TBS +
0.1% (v/v) Tween-20) before being incubated for 2 h, at
room temperature, with 100 l GST-RACK1 solution in
TBS. The GST-RACK1 solution was formed from a range of
dilutions over the concentration range 50 pM – 2 M.
Plates were then washed as above with protein complex
formation being detected by the addition of anti-RACK1
monoclonal antibody followed by peroxidase conjugated
anti-mouse IgM. These antibodies were both used at
1:2500 in TBS for 1 h at room temperature with a wash
step in between. Immunoreactivity was visualized by add-
ing ABTS solution (0.4 mM 2,2'-azino-bis [3-ethylbenz-
thiazoline-6-sulfonic acid] in 50 mM sodium citrate pH
4.0 plus 36 l 30% (vol/vol) H2O2 just prior to use) and
quantified using an MRX plate reader set at a wavelength
of 405 nm.
Molecular modeling
A comparative model of RACK1 was constructed with the
program Modeller [54], using bovine transducin G as the
structural template. The G subunit was extracted from a
G protein heterotrimer structure [45] with coordinate file
identifier 1 got in the protein structural data bank. The un-
derlying sequence alignment between RACK1 and the G
template followed that given previously [46], except for
WD repeats 6 and 7 where the sequence match is less clear
and structural factors were used to make small adjust-
ments. In particular, putative -strands in RACK1 were
identified through alignment of stretches of non-polar
residues with the known -strands of the G subunit,
which are also predominantly non-polar. This adjustment
aligned W339, N340 of G with W310, Q311 of RACK1.
Analysis of the RACK1 comparative model in terms of
binding the N-terminal region of PDE4D5 focussed on
WD repeats 5–7. Molecular surfaces were drawn for WD
repeats 5–7 that lack the start of WD repeat 5, since this re-
gion would form the outer -strand of an otherwise ab-
sent propeller 4, and is therefore unlikely to exhibit
structural order in the experimental WD repeat 5–7 con-
struct. The N-terminal region of PDE4D5 implicated in
binding to RACK1 by mutational analysis was modelled
as mainly -helical polypeptide, with the potential for
non-helical linker regions. Binding surfaces on RACK1
and PDE4D5 were assigned from the mutation affects on
binding, and their combination in a general model for
complexation used these data as well as overall comple-
mentarity of surface shape and polarity. Computer pro-
grams QUANTA (Accelrys) and Swiss-PDB Viewer [55]
were used for manipulation and display.
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